Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO versus SITAGLIPTIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO versus SITAGLIPTIN PHOSPHATE.
JENTADUETO vs SITAGLIPTIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Jentadueto is a combination of linagliptin and metformin. Linagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP) and enhancing glucose-dependent insulin secretion while suppressing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that slows the inactivation of incretin hormones (GLP-1 and GIP), thereby increasing their levels and prolonging their action. This enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner.
Administered orally twice daily with meals. Initial dose: one tablet JENTADUETO 5 mg/500 mg or 5 mg/1000 mg; subsequent titration based on glycemic response. Maximum daily dose: linagliptin 5 mg, metformin 2000 mg.
100 mg orally once daily.
None Documented
None Documented
Linagliptin: terminal t1/2 ~12 hours (long binding to DPP-4). Metformin: terminal t1/2 ~6.2 hours (renal impairment prolongs).
Terminal elimination half-life: 12.4 hours (range 8–14 hours). Clinically, supports once-daily dosing with gradual onset of DPP-4 inhibition.
Renal: linagliptin ~5% unchanged; metformin ~90% unchanged. Fecal: linagliptin ~80% (mostly unchanged). Biliary: minimal.
Renal excretion: ~87% (as unchanged drug in urine); biliary/fecal: ~13% (as metabolites and unchanged drug).
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor